Table 1 Baseline characteristics of the study groups
|  | Total (n = 60) | Liraglutide (n = 30) | Metformin (n = 30) | p |
|---|---|---|---|---|
Age, years | 51 ± 12 | 51 ± 10 | 50 ± 12 | 0.594 |
Male sex, % (n) | 66.7 (40) | 66.7 (20) | 66.7 (20) | 0.896 |
Smoking, % (n) | 36.6 (22) | 36.7 (11) | 36.7 (11) | 0.782 |
Hypertension, % (n) | 55 (33) | 56.7 (17) | 53.3 (16) | 0.270 |
Dyslipidemia, % (n) | 51.6 (31) | 53.3 (16) | 50 (15) | 0.410 |
Family history CAD, % (n) | 20 (12) | 20 (6) | 20 (6) | 0.804 |
Creatinine, mg/dl | 1.0 ± 0.2 | 1.1 ± 0.2 | 1.0 ± 0.3 | 0.733 |
eGFR, ml/min | 85 ± 9 | 85 ± 8 | 83 ± 11 | 0.315 |
Medication | ||||
 Beta blockers, % (n) | 18.3 (11) | 16.7 (5) | 20 (6) | 0.492 |
 Calcium antagonists, % (n) | 30 (18) | 33.3 (10) | 26.7 (8) | 0.231 |
 ACE-I, ARB, % (n) | 31.7 (19) | 30 (9) | 33.3 (10) | 0.913 |
 Diuretics, % (n) | 13.3 (8) | 13.3 (4) | 13.3 (4) | 0.984 |
 Statins, % (n) | 43.3 (26) | 46.7 (14) | 40 (12) | 0.292 |